Antiplatelet medications

31,114views

00:00 / 00:00

Flashcards

Antiplatelet medications

of complete

Questions

USMLE® Step 1 style questions USMLE

of complete

USMLE® Step 2 style questions USMLE

of complete

A 68-year-old woman is brought to the emergency department with sudden onset of epigastric and chest pain accompanied by sweating for the past hour. The patient’s symptoms improved with aspirin and sublingual nitroglycerin administered by the paramedics. An ECG is shown below. Troponin levels are normal. She is started on conventional therapy for unstable angina. Upon re-evaluation, the patient’s chest pain is not improved, and another drug is administered to reduce the risk of coronary thrombosis. At the same time, she is scheduled for percutaneous coronary intervention later today. Which of the following best describes the mechanism of action of this drug?
 
Reproduced from Flickr

External References

First Aid

2024

2023

2022

2021

Abciximab p. 120

Glycoprotein IIb/IIIa inhibitors p. 442

thrombogenesis and p. 417

Antiplatelet antibodies p. 727

abciximab as p. 120

Transcript

Watch video only

Antiplatelet medications prevent blood clot formation during hemostasis, where hemo means blood, and stasis means to halt or stop.

Hemostasis is divided into primary hemostasis, where circulating cell fragments called platelets form a plug at the site of an injured blood vessel, and secondary hemostasis, which involves multiple coagulation factors working together to form a fibrin mesh to stabilize the platelet plug.

Antiplatelet medications inhibit the steps of primary hemostasis to prevent the platelet plug from forming.

Primary hemostasis can be further divided into five steps: endothelial injury, exposure, adhesion, activation, and aggregation.

Endothelial injury is when the innermost layer of the artery, called the endothelium, gets damaged.

The second step is exposure, where the damaged endothelium exposes the underlying collagen.

The underlying collagen and endothelial cells then release a protein called Von Willebrand's factor, or vWF, that binds to this collagen.

The third step is adhesion where circulating platelets bind to the vWF via a surface protein called GPIB. The fourth step is activation, where platelets become active after binding to vWF.

First, the platelet changes shape and its membrane forms tentacle-like arms allowing it to grab onto other platelets.

Second, platelets release more vWF, as well as serotonin, a tiny molecule that attracts more platelets to the area.

Third, the platelets also release adenosine diphosphate or ADP, and thromboxane A2, or TXA2. These two molecules can activate other platelets that haven’t bound to vWF.

ADP and TXA2 also cause platelets to express new surface proteins called GPIIb/IIIa, which is needed for the fifth step, aggregation.

Now each platelet has multiple GPIIb/IIIa receptors that can bind to circulating proteins called fibrinogen. When two platelets attach to the same fibrinogen protein, they are linked together.

This allows platelets to rapidly aggregate at the site of injury, and form a large platelet plug that can stop the bleeding. Now, antiplatelet medications interfere at different steps during this process.

Aspirin, the NSAID or non-steroidal anti-inflammatory drug, has antiplatelet effects by blocking the synthesis of thromboxane A2, which activates platelets.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Not all (N)SAID and done: Effects of nonsteroidal anti‐inflammatory drugs and paracetamol intake on platelets" Research and Practice in Thrombosis and Haemostasis (2019)
  7. "Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention" Interventional Medicine and Applied Science (2016)
  8. "The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue" Andrology (2019)
Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX